Corona Remedies Share Price Target 2027: Is Rs 3,049 Realistic? Bull Case Points to Rs 3,652

Investors weighing a Corona Remedies target price for 2027 should start with where the stock sits today. At Rs 2,539.40 on 10 November 2026, it is 6.6% below its 52-week high of Rs 2,719.30 and 90.0% above its 52-week low of Rs 1,336.60. That range spans 103% from low to high, so the entry point matters as much as the Corona Remedies price forecast itself.

This article builds the Corona Remedies share price target from reported numbers only: four years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.

Click Here – Get Free Investment Predictions

Corona Remedies Stock Analysis: Company Overview and Key Stats

Corona Remedies (NSE: CORONA) has a market capitalisation of Rs 15,539 crore. In FY26 it reported revenue of Rs 1,414 crore and net profit of Rs 185.12 crore. The table collects the figures the Corona Remedies share price target is built on.

Metric	Value
Company	Corona Remedies
NSE Ticker	CORONA
CMP (10 November 2026)	Rs 2,539.40
52-Week High	Rs 2,719.30
52-Week Low	Rs 1,336.60
Market Cap	Rs 15,539 crore
PE Ratio (TTM)	75.06
Industry PE	40.13
Price to Book	19.30
Return on Equity	25.71%
Debt to Equity	0.14
EPS (TTM)	Rs 33.85
Dividend Yield	0.39%
12-Month Base Target	Rs 3,049
Bull Case	Rs 3,652
Downside Risk Level (not a target)	Rs 2,033

Why Is Corona Remedies Share Price Target Set at Rs 3,049 for 2027?

The arithmetic is short. Trailing EPS of Rs 33.85 grown for one year gives a forward EPS estimate of Rs 40.62, and multiplying it by the unchanged PE of 75.06 gives the Rs 3,049 base-case Corona Remedies stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Corona Remedies Target Price: Four Years of Results

Corona Remedies grew revenue from Rs 891.10 crore in FY23 to Rs 1,414 crore in FY26, a compound annual growth rate of 16.6%. Net profit grew faster, from Rs 84.93 crore to Rs 185.12 crore (29.7% a year), which shows margin gains did part of the work and not just higher sales.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY23	891.10	84.93	14.57	2.77
FY24	1,020.93	90.50	14.80	3.70
FY25	1,202.35	149.43	24.43	7.31
FY26	1,413.83	185.12	30.27	10.00

FY26 revenue growth was 17.6%, close to the three-year average of 16.6%, and net profit moved up 23.9%. EPS rose from Rs 14.80 in FY24 to Rs 30.27 in FY26. The FY27 outlook for the Corona Remedies price target depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Corona Remedies converted 13.1% of FY26 revenue into net profit, against 12.4% in FY25, within a four-year range of 8.9% to 13.1%. EBITDA margin was 20.2% in FY26 versus 20.5% in FY25.

In the September 2026 quarter, revenue was Rs 443.65 crore, up 22.1% from the same quarter a year earlier, while net profit of Rs 60.31 crore was up 15.3%. EBITDA came in at Rs 98.43 crore, up 21.9% year on year. The next quarterly result is the first test of whether the earnings assumption behind the Corona Remedies stock target holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.14, and shareholders' equity grew from Rs 408.52 crore in FY23 to Rs 746.86 crore in FY26. Operating cash flow in FY26 was Rs 229.48 crore against capital expenditure of Rs 174.13 crore, leaving free cash flow of Rs 55.35 crore, or 0.4% of the current market capitalisation. In FY25 free cash flow was Rs 98.83 crore.

Valuation Check for the Corona Remedies Stock Target: PE, Price to Book and ROE

At a PE of 75.06 against an industry PE of 40.13, Corona Remedies trades at a premium to its industry. Price to book is 19.30 on a book value of Rs 131.64 per share, and return on equity is 25.71%. A PE of 75.06 equals an earnings yield of 1.3%, and the FY26 dividend of Rs 10.00 per share gives a yield of 0.39%.

Shareholding Pattern and Institutional Holding

Promoters held 69.00% of Corona Remedies in September 2026, and promoter holding has stayed near 69.00% since December 2025. Foreign institutional investors (FII) held 4.21% and domestic institutions (DII) held 16.45%, which puts total institutional holding at 20.66%. FII holding rose from 1.84% in December 2025 to 4.21% in September 2026. Public shareholders own the remaining 10.34%. A meaningful institutional holding adds a layer of research coverage and trading depth.

Corona Remedies Share Price Targets for the Short Term and 12 Months

Short Term Corona Remedies Stock Target Levels: Technical Setup

At Rs 2,539.40 on 10 November 2026, Corona Remedies trades above its 50-day simple moving average of Rs 2,138.57 and above its 200-day exponential moving average of Rs 1,911.79. The 14-day RSI reads 85.7, which is overbought territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 2,719.30 (52-week high) and the nearest support is Rs 2,138.57 (50-day simple moving average). A sustained move above Rs 2,719.30 would improve the short-term setup, while a close below Rs 2,138.57 would shift attention to the next support.

12 Month Corona Remedies Target Price for 2027

The 12-month target of Rs 3,049 means a move of 20.1% up from Rs 2,539.40 over the next 12 months. It would also push the stock above its 52-week high of Rs 2,719.30. Anyone checking the Corona Remedies share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.

How EPS Growth and PE Multiple Change the Corona Remedies Target Price

EPS Growth	PE 60.05	PE 75.06	PE 86.32
0.0% (EPS Rs 33.85)	Rs 2,033	Rs 2,541	Rs 2,922
20.0% (EPS Rs 40.62)	Rs 2,439	Rs 3,049	Rs 3,506
25.0% (EPS Rs 42.31)	Rs 2,541	Rs 3,176	Rs 3,652

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Corona Remedies price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Corona Remedies Stock Target in 2027

Bull Case Rs 3,652

The bull case Corona Remedies price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 42.31, and a PE multiple that rises 15% to 86.32. That gives Rs 3,652, 43.8% above the current price and above the 52-week high of Rs 2,719.30, so the stock would have to set a fresh 52-week high.

Downside Risk Level Rs 2,033

The downside risk level is not a target. It assumes EPS stays flat at Rs 33.85 and the PE falls 20% to 60.05. That gives Rs 2,033, 19.9% below the current price and above the 52-week low of Rs 1,336.60.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	25.0%	86.32	Rs 3,652	+43.8%
Base Case	20.0%	75.06	Rs 3,049	+20.1%
Downside Risk	0.0%	60.05	Rs 2,033	-19.9%

Key Risks to the Corona Remedies Target Price for 2027

Growth Slowdown Risk for the Corona Remedies Price Target

Revenue in the September 2026 quarter was up 22.1% year on year, and FY26 revenue growth was 17.6%. If growth slows from here, the EPS estimate behind the Corona Remedies stock target will need revising.

Liquidity and Size Risk

Corona Remedies has a market capitalisation of Rs 15,539 crore. Institutional holding is 20.66%, and promoters hold 69.00%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.

Valuation and Margin Risk

Net margin was 13.1% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 75.06 versus an industry PE of 40.13, a de-rating toward the downside-risk PE of 60.05 would cut the price even if earnings hold.

Market and Technical Risk

Technical indicators add short-term risk: the 14-day RSI is 85.7 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time. That applies to any Corona Remedies stock target, however carefully it is built.

How to Invest in Corona Remedies

Start with the live price and volume. Any Corona Remedies share price target is only as current as the data behind it, and the data here is as of 10 November 2026, so refresh the Rs 2,539.40 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Corona Remedies' PE, ROE, debt and shareholding in one place.

Check Corona Remedies fundamentals on the Univest Screener

Then compare the three Corona Remedies target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Corona Remedies live price and get daily stock recommendations.

Conclusion

The Corona Remedies share price target for 2027 is Rs 3,049 in the base case, with Rs 3,652 as the bull case. The support for that view is arithmetic you can check: EPS grew 43.0% a year over FY24 to FY26, and the stock trades at a PE of 75.06. The risks are equally concrete, including a PE of 75.06 that sits above the industry PE of 40.13 and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework for judging the Corona Remedies price target, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Corona Remedies Share Price Target 2027

What is the Corona Remedies share price target for 2027?

Ans. The base-case Corona Remedies share price target for 2027 is Rs 3,049, which is 20.1% above the price of Rs 2,539.40 on 10 November 2026. The bull case is Rs 3,652 and the downside risk level, which is not a target, is Rs 2,033. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.

What is the Corona Remedies share price today?

Ans. As of 10 November 2026, 9:32 AM IST, Corona Remedies (NSE: CORONA) trades at Rs 2,539.40, up 0.21% on the day. That is 6.6% below the 52-week high of Rs 2,719.30 and 90.0% above the 52-week low of Rs 1,336.60. The market capitalisation of Rs 15,539 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.

Is Corona Remedies a buy or sell at the current price?

Ans. The data points both ways. On the positive side, EPS has grown 43.0% a year over FY24 to FY26 and the base case implies 20.1% upside; on the cautious side, the PE of 75.06 sits above the industry PE of 40.13, and the downside risk level of Rs 2,033 is 20% below the current price. Whether Corona Remedies fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.

What are the bull case target and downside risk level for Corona Remedies shares?

Ans. The bull case in the Corona Remedies share price target for 2027 is Rs 3,652, which assumes 25.0% EPS growth and a PE of 86.32, a 15% re-rating from today's multiple. That is 43.8% above the current price and above the 52-week high of Rs 2,719.30, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 2,033, which assumes flat EPS and a PE of 60.05, 20% lower than today. It sits 19.9% below the current price and above the 52-week low of Rs 1,336.60, and it marks a risk to watch, not a target.

What are the main risks to the Corona Remedies price target?

Ans. Four risks matter most for the Corona Remedies share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 15,539 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 60.05 would cut the price even if earnings hold.

What is the PE ratio of Corona Remedies and how does it compare with the industry?

Ans. The PE ratio of Corona Remedies is 75.06, against an industry PE of 40.13, which is a premium to the industry. Price to book is 19.30 and return on equity is 25.71%, and the PE equals an earnings yield of 1.3%. The base case holds the PE unchanged, so the Corona Remedies share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.

Who owns Corona Remedies, and what is the promoter holding?

Ans. Promoters held 69.00% of Corona Remedies in September 2026. FII held 4.21%, DII held 16.45% and the public held 10.34%. Together the two institutional groups hold 20.66%. Shareholding is filed every quarter, so it is worth rechecking after each result.

What were Corona Remedies' latest quarterly results?

Ans. In the September 2026 quarter, Corona Remedies reported revenue of Rs 443.65 crore (up 22.1% year on year) and net profit of Rs 60.31 crore (up 15.3%). For comparison, FY26 full-year revenue growth was 17.6% and net profit moved up 23.9%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.